NASDAQ:ICLR - Icon Stock Price, News, & Analysis

Icon trades on the NASDAQ under the ticker symbol "ICLR."

Icon Plc (NASDAQ:ICLR) announced its quarterly earnings data on Wednesday, July, 25th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.48 by $0.17. The medical research company earned $641.60 million during the quarter, compared to analyst estimates of $618.64 million. Icon had a return on equity of 26.35% and a net margin of 13.69%. The company's revenue was up 48.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.34 EPS. View Icon's Earnings History.

Icon is scheduled to release their next quarterly earnings announcement on Thursday, October, 25th 2018. View Earnings Estimates for Icon.

8 equities research analysts have issued 12-month price objectives for Icon's stock. Their predictions range from $120.00 to $157.00. On average, they anticipate Icon's share price to reach $144.1250 in the next twelve months. This suggests that the stock has a possible downside of 3.3%. View Analyst Price Targets for Icon.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Icon in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Icon.

Some companies that are related to Icon include Iqvia (IQV), Incyte (INCY), EXACT Sciences (EXAS), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), Exelixis (EXEL), BTG (BTGGF), Medpace (MEDP), Intrexon (XON), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX) and VIRALYTICS Ltd/S (VRACY).

News coverage about ICLR stock has trended somewhat positive recently, Accern reports. The research group ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Icon earned a news and rumor sentiment score of 0.18 on Accern's scale. They also assigned media headlines about the medical research company an impact score of 46.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for Icon.

Icon's stock is owned by a number of of retail and institutional investors. Top institutional investors include WCM Investment Management CA (8.57%), Acadian Asset Management LLC (4.02%), Earnest Partners LLC (4.02%), Renaissance Technologies LLC (3.58%), Boston Partners (3.08%) and FMR LLC (2.96%).

ICLR stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Millennium Management LLC, Wells Fargo & Company MN, Victory Capital Management Inc., Wasatch Advisors Inc., Systematic Financial Management LP, Mckinley Capital Management LLC Delaware and Janus Henderson Group PLC.

ICLR stock was purchased by a variety of institutional investors in the last quarter, including WCM Investment Management CA, Partner Fund Management L.P., Advisors Asset Management Inc., Redwood Investments LLC, Envestnet Asset Management Inc., Massachusetts Financial Services Co. MA, Boston Partners and Cornerstone Wealth Management LLC.

Shares of ICLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ICLR stock can currently be purchased for approximately $149.00.

Icon has a market capitalization of $7.94 billion and generates $1.76 billion in revenue each year. The medical research company earns $281.48 million in net income (profit) each year or $5.39 on an earnings per share basis. Icon employs 13,250 workers across the globe.

Icon's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The medical research company can be reached via phone at 353-1291-2000.